Targets › TGFB1
18 programs from 17 companies in 45 trials: 22 Phase 2, 14 Phase 1, 8 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Dec 2026.
Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively..; FUNCTION: [Latency-associated peptide]: Required to maintain the Transforming growth factor beta-1 (TGF-beta-1) chain in a latent state during storage in extracellular matrix.…. (UniProt, P01137)
Open in Phaseline: the race on TGFB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Luspatercept (ACE-536) Transforming growth factor beta inhibitor | TGFB1, TGFB2, TGFB3 | Phase 4 | Anemia; Myelodysplastic Syndromes; Beta-thalassemia; CCUS Clonal Cytopenia of Undetermined Significance … | Jul 2027 |
| Bristol-Myers Squibb | Luspatercept (ACE-536) Transforming growth factor beta inhibitor | TGFB1, TGFB2, TGFB3 | Phase 3 | Myelodysplastic Syndromes; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders; Beta-Thalassemia | Sep 2027 |
| Shanghai Chia Tai Tianqing Pharmaceutical Technology Development | TQB2868 Injection PD-L1 and TGF-β dual antibody | CD274, TGFB1 | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | May 2028 |
| Kolon TissueGene | TG-C (TissueGene-C) Non-transduced human chondrocytes combined with irradiated transduced human GP2-293 cells | TGFB1 | Phase 3 | Degenerative Osteoarthritis | – |
| National Cancer Institute (NCI) | Bintrafusp Alfa (M7824) Programmed cell death 1 ligand 1 binding agent; Transforming growth factor beta binding agent | CD274, TGFB1, TGFB2, TGFB3 | Phase 2 | Thymic Epithelial Tumor; Cancer Of Prostate; Kaposi Sarcoma; Urothelial Cancer | Dec 2026 |
| Bruno Bockorny | AGEN1423 Anti-CD73-TGFβ-Trap bifunctional antibody | NT5E, TGFB1 | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma | Apr 2027 |
| The First Affiliated Hospital of Zhengzhou University | SHR1701 PD-L1 and TGFβ dual inhibitor | PDCD1LG2, TGFB1 | Phase 2 | Advanced Gastric Cancer | Jul 2027 |
| Sirnaomics | STP705 siRNA targeting TGF-β1 and COX-2 for inflammation and adipose tissue remodeling inhibition | TGFB1, PTGS2 | Phase 2 | Submental Fullness | Jul 2027 |
| Bicara Therapeutics | Ficerafusp alfa (BCA101) Bispecific antibody targeting EGFR and TGF-β | EGFR, TGFB1 | Phase 2 | Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of Head and Neck (SCCHN) | Oct 2027 |
| The First Affiliated Hospital with Nanjing Medical University | Retlirafusp alfa Anti-PD-L1/TGF-β bifunctional fusion protein | PDCD1L1, TGFB1 | Phase 2 | Intrahepatic Cholangiocarcinoma (Icc) | Mar 2028 |
| University of Alabama at Birmingham | Pirfenidone Antifibrotic agent; reduces TGF-β signaling and inflammatory pathways | TGFB1 | Phase 2 | Recurrent Acute Pancreatitis | Sep 2028 |
| New Approaches to Neuroblastoma Therapy Consortium | Universal Donor (UD) TGFβi NK Cells TGFβ-inhibited universal donor natural killer cells | TGFB1 | Phase 2 | Neuroblastoma | Dec 2028 |
| FBD Biologics | HCB301 Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein | SIRPA, PDCD1LG2, TGFB1 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Pirfenidone TGF-beta pathway inhibitor | TGFB1 | Phase 1 | Multiple Sclerosis | Jan 2027 |
| Nationwide Children's Hospital | Universal Donor Natural Killer Cells (UD-NK) Ex vivo expanded natural killer cells with TGF-beta inhibition | TGFB1 | Phase 1 | Acute Myeloid Leukemia; High Grade Glioma | Feb 2027 |
| Kari Kendra | UD TGFbetai NK cells TGF-beta inhibitor-engineered natural killer cells | TGFB1 | Phase 1 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Apr 2027 |
| Second Affiliated Hospital of Guangzhou Medical University | GPC3 and/or TGFβ targeting CAR-T cells Engineered CAR-T cells targeting GPC3 and/or TGFβ with knockdown of PD1/HPK1, enhanced wit | GPC3, TGFB1 | Phase 1 | Hepatocellular Carcinoma | Aug 2029 |
| Baylor College of Medicine | DNR.NPC-specific T cells TGF-beta resistant EBV-specific cytotoxic T-lymphocytes | TGFB1 | Phase 1 | EBV-positive Nasopharyngeal Carcinoma | Feb 2033 |
Myelodysplastic Syndromes (8) Anemia (3) Metastatic Head and Neck Squamous Cell Carcinoma (2) Advanced Pancreatic Ductal Adenocarcinoma (1) Submental Fullness (1) Thymic Epithelial Tumor (1) Cancer Of Prostate (1) Kaposi Sarcoma (1) Urothelial Cancer (1) Advanced Solid Tumor (1) Clinical Stage IV Cutaneous Melanoma AJCC v8 (1) Degenerative Osteoarthritis (1)
small molecule (8), mixed (4), other (3), antibody (2), protein or peptide (1)
Bristol-Myers Squibb (2) Bruno Bockorny (1) Sirnaomics (1) National Cancer Institute (NCI) (1) FBD Biologics (1) Kari Kendra (1) Kolon TissueGene (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development (1) Nationwide Children's Hospital (1) Baylor College of Medicine (1) Second Affiliated Hospital of Guangzhou Medical University (1) The First Affiliated Hospital with Nanjing Medical University (1) The First Affiliated Hospital of Zhengzhou University (1) Bicara Therapeutics (1) New Approaches to Neuroblastoma Therapy Consortium (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) University of Alabama at Birmingham (1)
TGFB2 (3) TGFB3 (3) CD274 (2) PDCD1LG2 (2) NT5E (1) PTGS2 (1) SIRPA (1) GPC3 (1) PDCD1L1 (1) EGFR (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.